Development of an In Vitro Biopotency Assay for an AAV8 Hemophilia B Gene Therapy Vector Suitable for Clinical Product Release

by Johannes Lengler, Sogue Coulibaly, Bernadette Gruber, Reinhard Ilk, Josef Mayrhofer, Friedrich Scheiflinger, Werner Hoellriegl, Falko G. Falkner, Hanspeter Rottensteiner
Published 2020-06-01

Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever.

by Birgit Schäfer, Georg W Holzer, Alexandra Joachimsthaler, Sogue Coulibaly, Michael Schwendinger, Brian A Crowe, Thomas R Kreil, P Noel Barrett, Falko G Falkner
Published 2011-01-01

MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses.

by Annett Hessel, Helga Savidis-Dacho, Sogue Coulibaly, Daniel Portsmouth, Thomas R Kreil, Brian A Crowe, Michael G Schwendinger, Andreas Pilz, P Noel Barrett, Falko G Falkner, Birgit Schäfer
Published 2014-01-01

Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity.

by Annett Hessel, Michael Schwendinger, Georg W Holzer, Klaus K Orlinger, Sogue Coulibaly, Helga Savidis-Dacho, Marie-Luise Zips, Brian A Crowe, Thomas R Kreil, Hartmut J Ehrlich, P Noel Barrett, Falko G Falkner
Published 2011-01-01

A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.

by Annett Hessel, Michael Schwendinger, Daniela Fritz, Sogue Coulibaly, Georg W Holzer, Nicolas Sabarth, Otfried Kistner, Walter Wodal, Astrid Kerschbaum, Helga Savidis-Dacho, Brian A Crowe, Thomas R Kreil, P Noel Barrett, Falko G Falkner
Published 2010-01-01